Fleximat indications
Fleximat is a drug used for joint and muscular pain.
Fleximat description
Fleximat is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of joint and muscular pain.
Fleximat dosage
When Fleximat administered orally for replacement therapy in adults the initial dose is 20-30 mg, maintenance dose is 10.5 mg / day. If necessary, the initial dose is may be 15-100 mg / day, the maintenance one is 5-15 mg / day. The daily dose should be reduced gradually. For children the starting dose is 1-2 mg / kg in 4-6 receptions, the maintenance one is 300-600 mg / kg / day.
For IM or IV dose administration the multiplicity and duration of application are determined individually.
When intra-articular administration in large joints it used a dose of 25-50 mg, for medium-sized joints - 10-25 mg for small joints - 5-10 mg. For the introduction of infiltration into the tissues depending on disease severity and magnitude of the defeat use doses from 5 mg to 50 mg.
Fleximat used topically in ophthalmology 3 times / day, course of treatment is no more than 14 days; in dermatology - 1-3 times / day.
Fleximat interactions
When this drug applied simultaneously with:
- digoxin slightly increased concentration of digoxin in plasma.
- itraconazole greatly increases the concentration of atorvastatin in plasma, apparently due to inhibition of itraconazole its metabolism in the liver that occurs with the participation of isoenzyme CYP3A4; increased risk of myopathy.
- colestipol may decrease the concentration of atorvastatin in plasma, with lipid-lowering effect is enhanced.
- antacids containing magnesium hydroxide and aluminum hydroxide, reduce the concentration of atorvastatin by approximately 35%.
- cyclosporine, fibrates (including gemfibrozil), azole antifungals derivatives, nicotinic acid increases the risk of myopathy.
- erythromycin, clarithromycin moderately increased concentrations of atorvastatin in plasma, increases the risk of myopathy.
- ethinyl estradiol, norethisterone (norethindrone) slightly increases the concentration of ethinyl estradiol, norethisterone and (norethindrone) in blood plasma.
- protease inhibitors increases the concentration of Eto in plasma, as protease inhibitors are inhibitors of the CYP3A4 isoenzyme.
Diltiazem, verapamil, isradipine inhibit isoenzyme CYP3A4, which participates in the metabolism of Eto, so that while the use of these calcium channel blockers may increase the concentration of atorvastatin in plasma and increased risk of myopathy.
Fleximat side effects
Endocrine system: menstrual irregularities, suppression of adrenal function, Itsenko-Cushing's syndrome, suppression of pituitary-adrenal system, reduced tolerance to carbohydrates, steroid diabetes, or a manifestation of latent diabetes, growth retardation in children, delayed sexual development in children.
Digestive system: nausea, vomiting, steroid ulcer and duodenal ulcer, pancreatitis, esophagitis, bleeding and perforation of the gastrointestinal tract, increased or decreased appetite, flatulence, hiccups. In rare cases - elevated liver transaminases and alkaline phosphatase.
Metabolism: the negative nitrogen balance due to protein catabolism, increased excretion of calcium from the body, hypocalcemia, weight gain, increased sweating.
Cardiovascular system: the loss of potassium, hypokalemic alkalosis, arrhythmia, bradycardia (up to cardiac arrest); steroid myopathy, heart failure (the development or worsening of symptoms), ECG changes typical of hypokalemia, increased blood pressure, hypercoagulability, thrombosis. In patients with acute myocardial infarction - the spread of necrosis, slowing the formation of scar tissue that can lead to rupture of the heart muscle.
Musculoskeletal system: slowing growth and ossification processes in children (premature closure of epiphyseal growth zones) and osteoporosis (very rarely - pathological fractures, aseptic necrosis of the humeral head and femoral), rupture of tendons of muscles, muscle weakness, steroid myopathy, loss of muscle mass (atrophy).
CNS: headache, increased intracranial pressure, delirium, disorientation, euphoria, hallucinations, manic-depressive psychosis, depression, nervousness or anxiety, insomnia, dizziness, vertigo, pseudotumor cerebellum, and seizures.
Vision: the rear subcapsular cataracts, increased intraocular pressure (with the possible damage to the optic nerve), trophic changes of the cornea, exophthalmos, the propensity to develop secondary infections (bacterial, fungal, viral).
Dermatological reactions: petechiae, ecchymosis, thinning and fragility of the skin, hyper- or hypopigmentation, acne, stretch marks, susceptibility to the development of pyoderma and candidiasis.
Reactions due to immunosuppressive effect: slow process of regeneration, reduced resistance to infections.
For parenteral administration: in rare cases of anaphylactic and allergic reactions, hyper- or hypopigmentation, atrophy of skin and subcutaneous tissue, exacerbation after intrasinovialnogo applications such as Charcot arthropathy, sterile abscesses, when injected into pockets on the head - blindness.
Fleximat contraindications
Active ingredient matches for Fleximat:
Etofenamate in Turkey.
List of Fleximat substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Etover (Turkey) | |
| Flexo (Georgia, Turkey) | |
| Flexo Jel (Georgia) | |
| Flogojet (Chile, Peru) | |
| Gel; Topical; Etofenamate 5% (Andromaco) | |
| Flogol (Argentina) | |
| Flogol-Gel | |
| Flogoprofen (Ecuador, Hong Kong, Malta, Spain) | |
| Flogoprofen 5 % x 60 g (Chiesi) | |
| Flogoprofen 5 % x 100 mL (Chiesi) | |
| Gemadol (Italy, Sweden) | |
| Glasel (Germany) | |
| Herponil (Greece) | |
| Inalgex (Portugal) | |
| Irifone (Greece) | |
| Irifone 5% (Greece) | |
| Irifone Gel (Vietnam) | |
| Irifone Gel 1 tube 100 g | |
| Irifone Gel 1 tube 50 g | |
| Irifone Gel 50 mg/1 g x 1 tube 100 g | |
| Irifone Gel 50 mg/1 g x 1 tube 50 g | |
| Juve (Bosnia & Herzegowina) | |
| Kovotherm (Greece) | |
| Master-Gel (Chile) | |
| Gel; Topical; Etofenamate (Master) | |
| Melferut (Greece) | |
| Melferut 10% (Greece) | |
| Metotrop (Mexico) | |
| Nisolon (Taiwan) | |
| Nisolon 50 mg/1 g x 10 g (CCM Duopharma BioTech) | |
| Nisolon 50 mg/1 g x 15 g (CCM Duopharma BioTech) | |
| Nisolon 100 mg/1 g (CCM Duopharma BioTech) | |
| Nisolon 100 mg/1 g x 10 g (CCM Duopharma BioTech) | |
| Nisolon 100 mg/1 g x 15 g (CCM Duopharma BioTech) | |
| Nisolon 5 mg x 1000's (CCM Duopharma BioTech) | |
| Nisolon tab 5 mg 1000's (CCM Duopharma BioTech) | |
| Painex (Bangladesh, Portugal, Turkey) | |
| Tablet; Oral; Aspirin 375 mg; Caffeine Citrate 30 mg; Codeine Phosphate 15 mg (Mint) | |
| Tablet; Oral; Aspirin 375 mg; Caffeine Citrate 30 mg; Codeine Phosphate 30 mg (Mint) | |
| 100 mg x 2mlx10 (Mint) | |
| Painex 100mg INJ / 2mlx10 (Mint) | |
| PAINEX inj 100 mg x 2ml (Mint) | |
| Painex NA Gel (Mint) | $ 0.66 |
| PAİNEX | |
| Tablet; Oral; Aspirin 375 mg; Caffeine Citrate 30 mg; Codeine Phosphate 15 mg | |
| Tablet; Oral; Aspirin 375 mg; Caffeine Citrate 30 mg; Codeine Phosphate 30 mg | |
| 100 mg x 2mlx10 | |
| Painex 100mg INJ / 2mlx10 | |
| PAINEX inj 100 mg x 2ml (Mint) | |
See 171 substitutes for Fleximat | |
References
- PubChem. "ETOFENAMATE". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Etofenamate". http://www.drugbank.ca/drugs/DB08984 (accessed September 17, 2018).
- MeSH. "Anti-Inflammatory Agents, Non-Steroidal". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Fleximat are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Fleximat. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet1 consumer reported age
| Users | % | ||
|---|---|---|---|
| 46-60 | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
